Thursday, 15 October 2026European Markets

SPAREBANKEN ØST And BANK OF IRELAND GP Have A High Dividend Yield And Return On Equity In The Banks - Regional Industry.

Loading stream...

(VIANEWS) - SPAREBANKEN ØST (SPOG.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Banks - Regional industry.

Financial Asset Price Forward Dividend Yield Return on Equity
SPAREBANKEN ØST (SPOG.OL) kr54.64 9.79% 10.59%
BANK OF IRELAND GP (BIRG.IR) €9.98 6.14% 13.3%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. SPAREBANKEN ØST (SPOG.OL)

9.79% Forward Dividend Yield and 10.59% Return On Equity

Sparebanken Øst operates as a savings bank in Eastern Norway. The company offers financial products, such as savings, credit, and payment products; current accounts; home mortgage loans; and mortgage loans for new and used cars. It also provides vehicles, houses and contents, boats, and leisure insurance products, as well as life and health insurance products; and shares and funds trading services. In addition, the company buys, sells, and stores cryptocurrencies, as well as operates, manages, leases, and sells real estate properties. The company was founded in 1843 and is headquartered in Drammen, Norway.

Earnings Per Share

As for profitability, SPAREBANKEN ØST has a trailing twelve months EPS of kr7.75.

PE Ratio

SPAREBANKEN ØST has a trailing twelve months price to earnings ratio of 7.05. Meaning, the purchaser of the share is investing kr7.05 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.59%.

More news about SPAREBANKEN ØST.

2. BANK OF IRELAND GP (BIRG.IR)

6.14% Forward Dividend Yield and 13.3% Return On Equity

Bank of Ireland Group plc provides various banking and financial products and services. It provides current and savings accounts, and business deposits and accounts; personal, car, home improvement, graduate, motor finance, and student loans, as well as overdrafts; and business and farming loans, green business, insurance premium finance, invoice finance, hire purchase, and leasing services. The company also offers international payments and credit cards; protection overview, mortgage protection, life cover, specified illness cover, income protection, protection for individuals, and protection for families; pensions; investments; foreign exchange, treasury services, leveraged acquisition and property finance services; personal products; and premier and private banking services. In addition, it provides home, car, travel, and life insurance products. The company was founded in 1783 and is headquartered in Dublin, Ireland.

Earnings Per Share

As for profitability, BANK OF IRELAND GP has a trailing twelve months EPS of €1.4.

PE Ratio

BANK OF IRELAND GP has a trailing twelve months price to earnings ratio of 7.13. Meaning, the purchaser of the share is investing €7.13 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.3%.

Moving Average

BANK OF IRELAND GP's value is below its 50-day moving average of €10.15 and above its 200-day moving average of €9.08.

More news about BANK OF IRELAND GP.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com